



Project Name HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODI

[PEC Activity Diagram](#)


Industry Code 13 Pharmaceutical & Biotech

Project Type Grassroot

TIV (USD) 2,000,000,000

SIC Code 2836 Biological Products, Except Diagnostic Substances

Sector Final Formulation (Oral, Solid, Parenteral, Topical, etc.)



SIC Product 2836*0035 Cellular and Gene Therapy Products

Status Active

Last Update 23-Feb-2022

Initial Release 11-Jan-2021

Environmental Air (A) Land (L) Water (W)

Construction Labor Preference Union, Non-Unio

Operations Labor Preference Non-Union

Square Footage

New Sq. Ft. 2,000,000 Sq. Ft.

Plant Owner FUJIFILM Diosynth Biotechnologies U.S.A. Incorporated

Plant Parent FUJIFILM Holdings Corporation

Plant Name Holly Springs End-To-End Monoclonal Antibodies CDMO

Unit Name

Plant ID 3452553

Location 11751 New Hill Road, Oakview Innovation Park

Phone +1 919 468 9400

City/State Holly Springs, North Carolina 27540 U.S.A.

Zone/County NC*02, Wake

Project Responsibility Project Company

Project Contact

Project Executive FUJIFILM Diosynth Biotechnologies U.S.A. Incorporated
101 J Morris Commons Lane
Morrisville, North Carolina 27560
U.S.A.

Martin Meeson
Chief Executive Officer/President
[Tel.] +1 919 337 4400
[E-Mail] martin.meeson@fujifilm.com ; [LinkedIn] martinmeeson

Project Director FUJIFILM Diosynth Biotechnologies
Biogen Alle 1
Hillerod, Frederiksborg 3400
Denmark

Lars Petersen
Chief Operating Officer-Hillerod, Denmark Site
[Tel.] +45 774 16000 / [Alt.] +1 919 468 9400
[E-Mail] lars.petersen@fujifilm.com ; [LinkedIn] lars-petersen-5134362

Specification and Reliability FUJIFILM Diosynth Biotechnologies U.S.A. Incorporated
6051 George Watts Hill Drive

Morrisville, North Carolina 27709
U.S.A.

Thom Schmalzbauer
Head of Secondary Buildings and Site Development
[Tel.] +1 919 468 9400
[E-Mail] thom.schmalzbauer@fujifilmdb.com ; [LinkedIn] thom-schmalzbauer-676111205

Specification and Reliability FUJIFILM Diosynth Biotechnologies U.S.A. Incorporated
6051 George Watts Hill Drive
Morrisville, North Carolina 27709
U.S.A.

David Henry
Head of Engineering Technology
[Tel.] +1 919 468 9400
[E-Mail] david.henry@fujifilmdb.com ; [LinkedIn] david-henry-2794216

Contracts Administrator FUJIFILM Diosynth Biotechnologies U.S.A. Incorporated
6051 George Watts Hill Drive, (Morrisville)
Morrisville, North Carolina 27709
U.S.A.

Neal Falcone
Head of North America Procurement
[Tel.] +1 919 468 9400
[E-Mail] neal.falcone@fujifilm.com

EPC Jacobs Engineering Group/Jacobs Field Services
111 Corning Road Suite 200

Cary, North Carolina 27518
U.S.A.

Heather Boetger (Beecher)
Advanced Facilities Construction Business Manager
[Tel.] +1 919 859 5000
[E-Mail] heather.beecher@jacobs.com ; [LinkedIn] heather-boetger-beecher-87a96b23

EPC Jacobs Engineering Group/Jacobs Field Services
111 Corning Road Suite 200
Cary, North Carolina 27518
U.S.A.

Mark O'Brien
Procurement Manager
[Tel.] +1 919 859 5000
[E-Mail] mark.obrien@jacobs.com

EPC Jacobs Engineering Group/Jacobs Field Services
111 Corning Road Suite 200
Cary, North Carolina 27518
U.S.A.

William Harral
Subcontracts Manager
[Tel.] +1 919 859 5000
[E-Mail] william.harral@jacobs.com ; [LinkedIn] william-harral-027b0117

EPC Jacobs Engineering Group/Jacobs Field Services
111 Corning Road Suite 200
Cary, North Carolina 27518
U.S.A.

Glenn Wakefield
Manager of Projects
[Tel.] +1 919 859 5024 / [Alt.] +1 863 899 3263 (Mobile)
[E-Mail] glenn.wakefield@jacobs.com ; [LinkedIn]

PEC® Timing E2**PEC® Activity Site Preparation****Project Probability** High (81-99%)

Scope Fujifilm Diosynth with Jacobs performs Site Preparation for Grassroot End-To-End Biopharmaceuticals Monoclonal Antibodies CDMO Plant "Project Galaxy". DETAILS: Within 140-acre Oakview Innovation Park, in a series of phases, construct 2,000,000+ sqft building(s) and equip for the end-to-end (vertically integrated) contract production (8) 20,000L initial capacity, expandable to (32) 20,000L bioreactor capacity) of monoclonal antibodies and mammalian cell cultures of bulk drug substances with aseptic fill/finish, device assembly (syringes), packaging and labeling services. REQUIRES: Building(s), Temperature and Humidity Controls, Building Management Systems (BMS), Industrial Gas Supply and Storage, Air/Gas Vacuum System, Voice/Data/Wireless System, Compressors (Air), Fire and Security Systems, Bioreactors (8x20,000L), Aseptic Fill/Finish Equipment, Water-For-Injection Systems/Loops (WFI), Cleanrooms (ISO 5-8/Class 100-100,000), Automation Controls (PLC/DCS), Compressors (Air), Clean Steam Generators, Automated and Semi-Automated Syringe Assembly Stations/Equipment, Cell Culture Tanks, Purification Equipment, Clarification Equipment, Chromatography Equipment, Centrifuges, Ultrafiltration/Diafiltration (UF/DF) Equipment, Depth Filtration Equipment, pH Meters, Aseptic Packaging Equipment, Bar Coding/Scanning/Labeling Equipment, Checkweighers, Cell Expansion Tanks, Refrigeration, Freezers, Water Purification System, Robotics, Laboratory Information Management System (LIMS), Electrical Distribution, NGF Boilers, Heat Exchangers, Cooling Towers, Chillers, Pumps, Motors, Valves, Laboratory Stations, Analytical Equipment, Data Recorders, Conveyors (Roller/Belt). ENVIRONMENTAL: (A) HEPA Filtration System, Fume Hoods, Scrubbers, Dust Collectors; (L) Containment; (W) Pre-Wastewater Treatment System, Stormwater Drainage System.

Schedule Fujifilm Diosynth with Jacobs continues with Site Preparation through 4Q21 (Dec). Fujifilm with Jacobs releases any remaining Equipment RFQs plus Subcontractor Bid Documents 4Q21 (Oct)-1Q25 (Mar). Site Preparation Kick-Off 4Q21 (Oct). Project Construction Kick-Off 1Q22 (Jan). Project Completion 3Q25 (Aug). **NOTE: For Jacobs vendors, sign up with Ariba Discovery Network (Jacobs uses them to vet subcontractors, but sometimes they hire direct). <https://service.ariba.com/Discovery.aw/125039028/aw?awh=r&awssk=CxNDhs02&dard=1&ancdc=1>. At present, the best way to contact Fujifilm and Jacobs contacts is by email. Jacobs and Fujifilm contacts have opted out of company phone/directory. Phone numbers will be updated when available. **

Project Milestones

AFE 202106

Sub Bid Doc 202110

Completion 31-Aug-2025

Precision YEAR

Equip RFQ 202110

Kick-Off 202201

Kickoff Slippage 0 Months

Duration 44 Months

Bidding Companies - Listing may be partial and subject to change

Company Name				Project Responsibility					
Jacobs Engineering Group/Jacobs Field Services				EPC					
NNE Pharmaengineering Incorporated				A&E					
<div>Engineering Contracting</div> <div>Project Key Needs</div> <div>Matter Phase</div> <div>Energy</div> <div>Buy</div> <div>Sell</div>	Civil	Electrical	Environmental HVAC	Instrumentation	Mechanical	Structural	Process		
	Civil	Electrical	Environmental HVAC	Instrumentation	Mechanical	Structural	General [G/C]		
	Civil/Site	Structural	Architectural	Control Room	Process Equip	Heat Transfer			
	Instrumentation	Electrical	Mechanical	HVAC	Storage	NDE			
	Piping/Fittings	Insulation/Coatings	Environmental	Utilities	Valves				
	Communications		Batch Process		Packaging				
		Material Handling							
		Liquid		Solid					
		Boiler		Generator					

Plant Standard Contacts

Functional/Actual Title	Contact Name/E-mail	Telephone/On-site	QC Date/LinkedIn ID
Plant Manager	Stephenie Robertson	[Phn.] +1 919 468 9400	Jun-2021
Vice President, Operations - Engineering, Supply Chain & EHS	stephenie.robertson@fujifilmdb.com	Yes	stephenie-robertson-72829712
Engineering Manager	David Henry	[Phn.] +1 919 468 9400	Oct-2021
Head of Engineering Technology	david.henry@fujifilmdb.com	Yes	david-henry-2794216
Utilities Manager	Thom Schmalzbauer	[Phn.] +1 919 468 9400	Oct-2021
Head of Secondary Buildings and Site Development	thom.schmalzbauer@fujifilmdb.com	Yes	thom-schmalzbauer-676111205

Historical Reports

Project Name	Report Date	TIV	Phase
MORRISVILLE RECOMBINANT BIOPHARMACEUTICALS CMO PLANT CELL CULTURE PLANT ADDITION	11-Jan-2021	2,000,000,000 USD	Site Selection (P1 -
HOLLY SPRINGS GRASSROOT END-TO-END BIOPHARM/CELL CULTURE CDMO PLANT	18-Mar-2021	2,000,000,000 USD	Owner Review of Is
HOLLY SPRINGS GRASSROOT END-TO-END BIOPHARM/CELL CULTURE CDMO PLANT	18-Mar-2021	2,000,000,000 USD	Owner Review of Is
HOLLY SPRINGS GRASSROOT END-TO-END BIOPHARM/CELL CULTURE CDMO PLANT	18-Mar-2021	2,000,000,000 USD	Owner Review of Is
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO PLANT	19-Mar-2021	2,000,000,000 USD	Owner Review of Is

HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	19-Mar-2021	2,000,000,000 USD	Owner Review of Is
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	22-Mar-2021	2,000,000,000 USD	Owner Review of Is
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	24-Mar-2021	2,000,000,000 USD	Owner Review of Is
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	24-Mar-2021	2,000,000,000 USD	Owner Review of Is
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	16-Apr-2021	2,000,000,000 USD	Owner Review of Is
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	28-Jun-2021	2,000,000,000 USD	Preliminary Design
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	29-Jun-2021	2,000,000,000 USD	Detailed Design (P
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	22-Jul-2021	2,000,000,000 USD	Detailed Design (P
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	31-Aug-2021	2,000,000,000 USD	Detailed Design (P
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	01-Sep-2021	2,000,000,000 USD	Preliminary Enginee
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	01-Sep-2021	2,000,000,000 USD	Preliminary Enginee
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	01-Sep-2021	2,000,000,000 USD	Preliminary Enginee
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	01-Sep-2021	2,000,000,000 USD	Preliminary Enginee
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	01-Sep-2021	2,000,000,000 USD	Preliminary Enginee
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	01-Sep-2021	2,000,000,000 USD	Preliminary Enginee
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	01-Sep-2021	2,000,000,000 USD	Preliminary Enginee
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	18-Oct-2021	2,000,000,000 USD	Site Preparation (E
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	18-Oct-2021	2,000,000,000 USD	Site Preparation (E
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	22-Oct-2021	2,000,000,000 USD	Site Preparation (E
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	07-Jan-2022	2,000,000,000 USD	Site Preparation (E
HOLLY SPRINGS GRASSROOT END-TO-END MONOCLONAL ANTIBODIES CDMO "PROJECT GALAXY"	23-Feb-2022	2,000,000,000 USD	Site Preparation (E